Eton Pharmaceuticals, Inc. (ETON)

Market Cap	422.38M
Revenue (ttm)	39.01M
Net Income (ttm)	-3.82M
Shares Out	26.82M
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	39.38
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100,846
Open	15.54
Previous Close	15.79
Day's Range	15.54 - 15.75
52-Week Range	3.15 - 18.41
Beta	1.34
Analysts	Strong Buy
Price Target	27.67 (+75.68%)
Earnings Date	May 8, 2025

About ETON

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, and commercializing pharmaceutical products for rare diseases. The company offers INCRELEX, treatment for children who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD); ALKINDI SPRINKLE, as a replacement therapy for Adrenocortical Insufficiency (“AI”) in children under 17 years of age, and accurate dosing for newborns and children with AI; GALZIN, as a maintenance treatment for patients with Wilson Disease who have been initially tr...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Nov 13, 2018
• Employees: 31
• Stock Exchange: NASDAQ
• Ticker Symbol: ETON
• Website: https://www.etonpharma.com

Financial Performance

In 2024, Eton Pharmaceuticals's revenue was $39.01 million, an increase of 23.29% compared to the previous year's $31.64 million. Losses were -$3.82 million, 308.4% more than in 2023.

Analyst Forecast

According to 3 analysts, the average rating for ETON stock is "Strong Buy." The 12-month stock price forecast is $27.67, which is an increase of 75.68% from the latest price.

Price Target

$27.67

(75.68% upside)

Analyst Consensus: Strong Buy